Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Amuvatinib has cytotoxic effects against NRAS-mutant melanoma but not BRAF-mutant melanoma.

Melanoma research - 1 Oct 2014

Fedorenko Inna V, Fang Bin, Koomen John M, Gibney Geoffrey T, Smalley Keiran S M

Abstract excerpt

Effective targeted therapy strategies are still lacking for the 15-20% of melanoma patients whose melanomas are driven by oncogenic NRAS. Here, we report on the NRAS-specific behavior of amuvatinib, a kinase inhibitor with activity against c-KIT, Axl, PDGFRα, and Rad51. An analysis of BRAF-mutant and NRAS-mutant melanoma cell lines showed the NRAS-mutant cohort to be enriched for targets of amuvatinib, including...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Axl Receptor Tyrosine Kinase
Share to Cell Culture Techniques

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Inhibitory Concentration 50

Share to Intercellular Signaling Peptides and Proteins

Share to Piperazines

Share to Proto-Oncogene Proteins c-kit

Share to Pyrimidines

Share to Receptor Protein-Tyrosine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 24950457
DOI: 10.1097/CMR.0000000000000103
PMCID: PMC4384823

Genes

NRAS
BRAF
KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Amuvatinib has cytotoxic effects against NRAS-mutant melanoma but not BRAF-mutant melanoma.PMID 24950457Read ↗

<em>NRAS</em>-mutant melanoma: current challenges and future prospectSemantic proximity Read ↗

Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma.Semantic proximity Read ↗

NRAS mutant melanoma: Towards better therapies.Semantic proximity Read ↗

Current Perspectives and Novel Strategies of NRAS-Mutant MelanomaSemantic proximity Read ↗

Targeting mutant NRAS signaling pathways in melanoma.Semantic proximity Read ↗

Binimetinib for the treatment of NRAS-mutant melanoma.Semantic proximity Read ↗

Mutant NRASQ61 shares signaling similarities across various cancer types--potential implications for future therapies.Semantic proximity Read ↗

Targeting the MAPK pathway for NRAS mutant melanoma: from mechanism to clinic.Semantic proximity Read ↗

Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gαq and Gα11 and kill uveal melanoma cellsSemantic proximity Read ↗

Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials.Semantic proximity Read ↗

613MO A phase I clinical trial evaluating exarafenib, a selective pan-RAF inhibitor in combination with binimetinib in NRAS-mutant (NRASMut) melanoma (Mel) & BRAF-altered solid tumorsSemantic proximity Read ↗

Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.